In ovarian cancer, we have shown that STIP1 binds to a bone morphogenetic protein (BMP) receptor – termed activin A receptor, type II-like kinase 2 (ALK2) – to activate the SMAD signaling pathway and the transcriptional activation of ID3 (inhibitor of DNA binding 3) [10]. Here, STIP1 is linked to ovarian carcinoma.